Cargando…

Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach

The aim of this study was to optimize the formulation of meloxicam (MEL)-containing human serum albumin (HSA) nanoparticles for nose-to-brain via a quality by design (QbD) approach. Liquid and dried formulations of nanoparticles containing Tween 80 and without the surfactant were investigated. Vario...

Descripción completa

Detalles Bibliográficos
Autores principales: Katona, Gábor, Balogh, György Tibor, Dargó, Gergő, Gáspár, Róbert, Márki, Árpád, Ducza, Eszter, Sztojkov-Ivanov, Anita, Tömösi, Ferenc, Kecskeméti, Gábor, Janáky, Tamás, Kiss, Tamás, Ambrus, Rita, Pallagi, Edina, Szabó-Révész, Piroska, Csóka, Ildikó
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076499/
https://www.ncbi.nlm.nih.gov/pubmed/31991767
http://dx.doi.org/10.3390/pharmaceutics12020097
_version_ 1783507231131566080
author Katona, Gábor
Balogh, György Tibor
Dargó, Gergő
Gáspár, Róbert
Márki, Árpád
Ducza, Eszter
Sztojkov-Ivanov, Anita
Tömösi, Ferenc
Kecskeméti, Gábor
Janáky, Tamás
Kiss, Tamás
Ambrus, Rita
Pallagi, Edina
Szabó-Révész, Piroska
Csóka, Ildikó
author_facet Katona, Gábor
Balogh, György Tibor
Dargó, Gergő
Gáspár, Róbert
Márki, Árpád
Ducza, Eszter
Sztojkov-Ivanov, Anita
Tömösi, Ferenc
Kecskeméti, Gábor
Janáky, Tamás
Kiss, Tamás
Ambrus, Rita
Pallagi, Edina
Szabó-Révész, Piroska
Csóka, Ildikó
author_sort Katona, Gábor
collection PubMed
description The aim of this study was to optimize the formulation of meloxicam (MEL)-containing human serum albumin (HSA) nanoparticles for nose-to-brain via a quality by design (QbD) approach. Liquid and dried formulations of nanoparticles containing Tween 80 and without the surfactant were investigated. Various properties, such as the Z-average, zeta potential, encapsulation efficacy (EE), conjugation of MEL and HSA, physical stability, in vitro dissolution, in vitro permeability, and in vivo plasma and brain distribution of MEL were characterized. From a stability point of view, a solid product (Mel-HSA-Tween) is recommended for further development since it met the desired critical parameters (176 ± 0.3 nm Z-average, 0.205 ± 0.01 PdI, −14.1 ± 0.7 mV zeta potential) after 6 months of storage. In vitro examination showed a significantly increased drug dissolution and permeability of MEL-containing nanoparticles, especially in the case of applying Tween 80. The in vivo studies confirmed both the trans-epithelial and axonal transport of nanoparticles, and a significantly higher cerebral concentration of MEL was detected with nose-to-brain delivery, in comparison with intravenous or per os administration. These results indicate intranasal the administration of optimized MEL-containing HSA formulations as a potentially applicable “value-added” product for the treatment of neuroinflammation.
format Online
Article
Text
id pubmed-7076499
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70764992020-03-20 Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach Katona, Gábor Balogh, György Tibor Dargó, Gergő Gáspár, Róbert Márki, Árpád Ducza, Eszter Sztojkov-Ivanov, Anita Tömösi, Ferenc Kecskeméti, Gábor Janáky, Tamás Kiss, Tamás Ambrus, Rita Pallagi, Edina Szabó-Révész, Piroska Csóka, Ildikó Pharmaceutics Article The aim of this study was to optimize the formulation of meloxicam (MEL)-containing human serum albumin (HSA) nanoparticles for nose-to-brain via a quality by design (QbD) approach. Liquid and dried formulations of nanoparticles containing Tween 80 and without the surfactant were investigated. Various properties, such as the Z-average, zeta potential, encapsulation efficacy (EE), conjugation of MEL and HSA, physical stability, in vitro dissolution, in vitro permeability, and in vivo plasma and brain distribution of MEL were characterized. From a stability point of view, a solid product (Mel-HSA-Tween) is recommended for further development since it met the desired critical parameters (176 ± 0.3 nm Z-average, 0.205 ± 0.01 PdI, −14.1 ± 0.7 mV zeta potential) after 6 months of storage. In vitro examination showed a significantly increased drug dissolution and permeability of MEL-containing nanoparticles, especially in the case of applying Tween 80. The in vivo studies confirmed both the trans-epithelial and axonal transport of nanoparticles, and a significantly higher cerebral concentration of MEL was detected with nose-to-brain delivery, in comparison with intravenous or per os administration. These results indicate intranasal the administration of optimized MEL-containing HSA formulations as a potentially applicable “value-added” product for the treatment of neuroinflammation. MDPI 2020-01-25 /pmc/articles/PMC7076499/ /pubmed/31991767 http://dx.doi.org/10.3390/pharmaceutics12020097 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Katona, Gábor
Balogh, György Tibor
Dargó, Gergő
Gáspár, Róbert
Márki, Árpád
Ducza, Eszter
Sztojkov-Ivanov, Anita
Tömösi, Ferenc
Kecskeméti, Gábor
Janáky, Tamás
Kiss, Tamás
Ambrus, Rita
Pallagi, Edina
Szabó-Révész, Piroska
Csóka, Ildikó
Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach
title Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach
title_full Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach
title_fullStr Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach
title_full_unstemmed Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach
title_short Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach
title_sort development of meloxicam-human serum albumin nanoparticles for nose-to-brain delivery via application of a quality by design approach
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076499/
https://www.ncbi.nlm.nih.gov/pubmed/31991767
http://dx.doi.org/10.3390/pharmaceutics12020097
work_keys_str_mv AT katonagabor developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT baloghgyorgytibor developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT dargogergo developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT gasparrobert developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT markiarpad developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT duczaeszter developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT sztojkovivanovanita developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT tomosiferenc developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT kecskemetigabor developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT janakytamas developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT kisstamas developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT ambrusrita developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT pallagiedina developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT szaboreveszpiroska developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach
AT csokaildiko developmentofmeloxicamhumanserumalbuminnanoparticlesfornosetobraindeliveryviaapplicationofaqualitybydesignapproach